Overview

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

Status:
Not yet recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This Study is A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

Phase:

Phase 3

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Botulinum Toxins, Type A